Astria Therapeutics (NASDAQ:ATXS) Rating Reiterated by HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 43.63% from the company’s current price.

Several other research firms have also weighed in on ATXS. TD Cowen assumed coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 price objective for the company. Oppenheimer raised their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Finally, Wedbush restated an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Astria Therapeutics has an average rating of “Buy” and a consensus target price of $25.20.

Astria Therapeutics Price Performance

Shares of ATXS stock opened at $11.14 on Friday. The stock’s fifty day simple moving average is $11.33 and its 200 day simple moving average is $10.83. Astria Therapeutics has a one year low of $4.26 and a one year high of $16.90. The firm has a market cap of $611.73 million, a price-to-earnings ratio of -4.80 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last issued its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). On average, research analysts anticipate that Astria Therapeutics will post -1.66 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Trexquant Investment LP bought a new position in Astria Therapeutics in the fourth quarter valued at about $409,000. Affinity Asset Advisors LLC raised its stake in shares of Astria Therapeutics by 46.6% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,466,465 shares of the biotechnology company’s stock worth $11,262,000 after buying an additional 466,165 shares during the last quarter. Armistice Capital LLC acquired a new position in Astria Therapeutics in the fourth quarter valued at approximately $12,119,000. ADAR1 Capital Management LLC acquired a new stake in Astria Therapeutics during the 4th quarter worth $1,469,000. Finally, Perceptive Advisors LLC raised its position in shares of Astria Therapeutics by 82.9% during the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock valued at $30,751,000 after acquiring an additional 1,814,608 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.